Context Therapeutics Inc. (NASDAQ:CNTX) Sees Significant Increase in Short Interest

Context Therapeutics Inc. (NASDAQ:CNTX) was the recipient of a significant growth in short interest in December. As of December 15th, there was short interest totalling 986,300 shares, a growth of 22.9% from the November 30th total of 802,800 shares. Based on an average trading volume of 525,700 shares, the days-to-cover ratio is presently 1.9 days. Approximately 1.7% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on CNTX. HC Wainwright reissued a “buy” rating and set a $6.00 price target on shares of Context Therapeutics in a report on Monday, September 23rd. D. Boral Capital assumed coverage on Context Therapeutics in a report on Monday, November 25th. They issued a “buy” rating and a $9.00 target price on the stock. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $6.80.

Context Therapeutics Stock Performance

Shares of NASDAQ CNTX traded down $0.01 during trading on Tuesday, reaching $1.05. The company had a trading volume of 1,444,265 shares, compared to its average volume of 363,450. Context Therapeutics has a 52 week low of $0.89 and a 52 week high of $2.75. The business’s 50 day moving average price is $1.67 and its 200-day moving average price is $1.98. The stock has a market cap of $78.75 million, a PE ratio of -1.15 and a beta of 2.00.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.11). Equities analysts anticipate that Context Therapeutics will post -0.51 earnings per share for the current year.

Hedge Funds Weigh In On Context Therapeutics

Large investors have recently made changes to their positions in the company. Y Intercept Hong Kong Ltd acquired a new stake in shares of Context Therapeutics during the third quarter worth $89,000. Renaissance Technologies LLC grew its position in shares of Context Therapeutics by 63.4% during the 2nd quarter. Renaissance Technologies LLC now owns 65,200 shares of the company’s stock worth $131,000 after buying an additional 25,300 shares during the period. State Street Corp raised its position in shares of Context Therapeutics by 21.5% in the 3rd quarter. State Street Corp now owns 111,907 shares of the company’s stock valued at $219,000 after acquiring an additional 19,800 shares during the period. Affinity Asset Advisors LLC boosted its stake in Context Therapeutics by 392.4% during the 2nd quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock worth $3,246,000 after acquiring an additional 1,290,323 shares during the last quarter. Finally, Franklin Resources Inc. acquired a new position in Context Therapeutics during the third quarter valued at approximately $3,689,000. Institutional investors and hedge funds own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.